Australia Antacids Market to Reach US$ 548.62 Million by 2034 – 5.03% CAGR Growth Forecast

Australia Antacids Market Outlook & Revenue Forecast (2026–2034)

Australia Antacids Market is expected to reach US$ 548.62 Million by 2034 from US$ 352.74 Million in 2025, with a CAGR of 5.03% from 2026 to 2034. Australia's antacids market is growing due to the rising prevalence of gastroesophageal reflux disease (GERD), unhealthy dietary habits, increasing demand for over-the-counter digestive remedies, expanding pharmacy and online retail availability, an aging population, and continuous innovation in fast-acting, convenient antacid formulations.

Australia Antacids Industry at a Glance

Antacids are over-the-counter medicines that neutralize excess stomach acid, providing rapid relief from heartburn, acid indigestion, gastroesophageal reflux (GERD), and sour stomach. They work by raising the stomach's pH, reducing irritation caused by gastric acid. Common active ingredients include calcium carbonate, magnesium hydroxide, aluminum hydroxide, and sodium bicarbonate. Antacids are available in chewable tablets, liquids, powders, and effervescent formulations, allowing consumers to choose products that best suit their preferences. They are widely used for occasional digestive discomfort and are easily accessible through pharmacies, supermarkets, and online platforms. However, prolonged or excessive use should be monitored under healthcare professional guidance.

Australia's antacids market is driven by the increasing prevalence of acid reflux, GERD, indigestion, and lifestyle-related digestive disorders. Growing consumption of processed foods, obesity, alcohol intake, and stressful lifestyles have contributed to rising demand for fast-acting over-the-counter digestive medicines. Consumers increasingly prefer self-medication, supported by the widespread availability of antacids through retail pharmacies, supermarkets, and e-commerce channels. The country's aging population also contributes to higher demand, as older adults experience gastrointestinal disorders more frequently. Furthermore, manufacturers continue introducing improved formulations with enhanced convenience and faster symptom relief, while digital pharmacy services and expanding healthcare awareness further strengthen long-term market growth across Australia.

Key Forces Accelerating Australia Antacids Market

Rising Burden of Acid Reflux and Lifestyle-Related Digestive Disorders

Australia is witnessing a steady increase in gastroesophageal reflux disease (GERD), heartburn, and acid indigestion due to changing dietary habits, obesity, alcohol consumption, smoking, and high-stress lifestyles. Busy schedules and frequent consumption of processed and convenience foods have increased demand for fast-acting over-the-counter antacids. Consumers increasingly prefer self-medication for mild digestive symptoms, supported by the widespread availability of antacids through pharmacies, supermarkets, and online retailers. Growing public awareness of digestive health and easier access to pharmacist consultations further encourage product adoption. Manufacturers continue investing in convenient dosage forms, improved flavors, and dual-action formulations to enhance consumer experience.

In August 2025, Reckitt Australia expanded its digestive health portfolio by introducing Gaviscon Chewing Gum in Australia, offering a portable, sugar-free antacid format for on-the-go heartburn relief. The launch reflects growing innovation in consumer-friendly digestive healthcare products and supports market expansion.

Expanding Over-the-Counter Healthcare and Product Availability

Australia's well-established over-the-counter (OTC) healthcare market continues to drive demand for antacids as consumers increasingly prefer self-management of occasional heartburn, acid reflux, and indigestion. Expanding pharmacy chains, supermarkets, and digital health platforms have significantly improved access to digestive health products across the country. Rising health awareness and pharmacist-led guidance further encourage consumers to seek fast-acting OTC solutions before consulting physicians. Manufacturers are continuously expanding their product portfolios with convenient formulations that cater to evolving consumer preferences, supporting market competitiveness.

In October 2025, Bayer Australia Ltd. secured Therapeutic Goods Administration (TGA) registration for Rennie Spearmint Flavour chewable tablets, expanding its antacid portfolio in Australia. The new product offers consumers an additional fast-acting option for relieving heartburn and acid indigestion, strengthening competition within the country's OTC digestive healthcare market.

Convenient On-the-Go Antacid Solutions Enhance Consumer Adoption

Australian consumers are increasingly seeking portable, fast-acting digestive health products that fit busy lifestyles. This trend has encouraged manufacturers to develop compact chewable tablets and single-dose formulations that provide rapid relief from heartburn, acid reflux, and indigestion without requiring water. Convenient packaging, improved flavors, and easy accessibility through pharmacies, supermarkets, and online retailers are increasing product adoption among working professionals and travelers. Continuous innovation in consumer-friendly dosage formats is expected to support long-term growth of Australia's antacids market.

In 2026, Mylanta 2GO Antacid Dual Action was listed with updated product information on Australia's national medicines information platform, offering chewable tablets containing alginic acid, magaldrate, and sodium bicarbonate for fast, long-lasting relief from heartburn, indigestion, and gastric reflux. The product reinforces the availability of convenient, portable antacid solutions for Australian consumers

Market Headwinds Facing Australia Antacids Sector

Excessive Self-Medication and Limited Professional Diagnosis

The widespread availability of over-the-counter antacids in Australia encourages consumers to self-manage heartburn and acid reflux without seeking medical advice. While these medicines provide rapid symptom relief, prolonged or frequent use can mask serious gastrointestinal conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, or even gastric cancer. Delayed diagnosis may lead to disease progression and increased healthcare costs. In addition, consumers may misuse antacids by exceeding recommended doses or using them alongside other medications without professional guidance, increasing the risk of drug interactions. Strengthening public awareness, pharmacist counseling, and timely medical evaluation for persistent symptoms will be essential to ensure safe antacid use and sustainable market growth.

Growing Preference for Alternative Acid-Suppressing Therapies

Australia's antacids market faces increasing competition from proton pump inhibitors (PPIs), H2-receptor antagonists, and lifestyle-based management approaches that provide longer-lasting relief for chronic acid-related disorders. Physicians frequently recommend these therapies for patients with persistent GERD, reducing reliance on traditional antacids for long-term treatment. Additionally, growing consumer awareness regarding dietary modifications, weight management, and preventive digestive health encourages non-pharmacological approaches to symptom control. The availability of generic acid-suppressing medicines at competitive prices further intensifies market competition. To remain competitive, antacid manufacturers must focus on product differentiation through faster-acting formulations, convenient dosage forms, improved flavors, and consumer education highlighting the benefits of immediate symptom relief for occasional heartburn and indigestion.

New South Wales: Australia's Largest Hub for Digestive Healthcare Demand

New South Wales dominates Australia's antacids market due to its large population, extensive healthcare infrastructure, and widespread retail pharmacy network. Sydney and surrounding metropolitan areas report significant demand for over-the-counter digestive health products, supported by busy urban lifestyles, high consumption of convenience foods, and increasing cases of acid reflux and indigestion. Community pharmacies, supermarkets, and online healthcare platforms ensure broad product accessibility. The state's aging population and growing awareness of gastrointestinal health further contribute to antacid consumption. Continuous expansion of digital pharmacy services, pharmacist-led consultations, and preventive healthcare initiatives strengthen consumer confidence in self-medication. These factors position New South Wales as the country's leading market for antacid products.

Victoria: Innovation and Retail Accessibility Supporting Market Growth

Victoria represents a major market for antacids, driven by strong healthcare services, high urbanization, and widespread availability of consumer healthcare products. Melbourne's extensive network of pharmacies, hospitals, and supermarket chains provides convenient access to leading antacid brands. Rising prevalence of lifestyle-related digestive disorders, increasing stress levels, and changing dietary habits continue to support market demand. Consumers increasingly prefer fast-acting OTC medicines for occasional heartburn and indigestion, while digital health platforms improve access to product information and pharmacist guidance. Continuous investment in healthcare awareness and preventive wellness initiatives encourages responsible self-care. Victoria's combination of strong retail infrastructure and health-conscious consumers supports sustained growth of the antacids market.

Queensland: Growing Consumer Awareness Driving OTC Antacid Adoption

Queensland's antacids market is expanding due to population growth, increasing healthcare accessibility, and rising awareness of digestive wellness. Urban centers such as Brisbane and the Gold Coast experience growing demand for over-the-counter digestive health products as changing dietary patterns and busy lifestyles contribute to heartburn and acid reflux. Community pharmacies play an essential role in guiding consumers toward appropriate self-care solutions. The state's tourism industry also supports demand for portable digestive health products through retail pharmacies and convenience stores. Increasing use of online pharmacy services and healthcare applications further improves consumer access to antacids. Continued expansion of primary healthcare services is expected to support stable market growth across Queensland.

Western Australia: Expanding Pharmacy Networks Enhancing Market Reach

Western Australia's antacids market is supported by improving healthcare accessibility, expanding pharmacy networks, and increasing consumer preference for self-medication. Perth serves as the state's primary healthcare and retail hub, where pharmacies, supermarkets, and online retailers offer a broad range of digestive health products. Rising prevalence of obesity, changing eating habits, and increasing awareness of acid reflux management contribute to growing antacid demand. Regional healthcare initiatives and digital pharmacy services are improving access to over-the-counter medicines across remote communities. Consumers increasingly seek convenient, fast-acting formulations for occasional digestive discomfort, encouraging manufacturers to strengthen distribution channels. These factors position Western Australia as a steadily growing market for antacid products within Australia.

Australia Proton Pump Inhibitors Market

Australia’s proton pump inhibitors (PPIs) market is supported by the widespread prevalence of gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related gastrointestinal disorders. Commonly used PPIs, including omeprazole, pantoprazole, esomeprazole, and lansoprazole, are available through prescription and over-the-counter channels, increasing consumer accessibility. Growing awareness regarding digestive health, an aging population, and rising demand for effective long-duration acid suppression therapies are supporting market expansion. Australia’s well-developed healthcare infrastructure and established pharmacy network further facilitate PPI distribution. Generic drug availability and competitive pricing encourage broader adoption, particularly among cost-conscious consumers. Meanwhile, concerns regarding prolonged PPI use, potential side effects, and increasing emphasis on appropriate medication management are encouraging healthcare professionals to promote responsible usage and periodic treatment evaluation.

Australia Antacids Tablets Market

Australia’s antacid tablets market is expanding due to increasing incidences of heartburn, acid indigestion, and occasional gastric discomfort among consumers. Antacid tablets provide rapid symptom relief by neutralizing excess stomach acid and are widely preferred for convenient, short-term management of digestive discomfort. Rising consumption of processed foods, irregular eating patterns, obesity, and sedentary lifestyles are contributing to digestive health concerns and supporting demand. The availability of chewable and flavored tablets through pharmacies, supermarkets, and online retail platforms improves accessibility and consumer convenience. Established pharmaceutical companies and private-label brands compete through product formulation, pricing, packaging, and brand recognition. Growing consumer awareness of digestive wellness is further supporting preventive and symptomatic treatment. However, increasing preference for alternative acid-reducing medicines and awareness regarding excessive self-medication may influence long-term market growth.

Australia Antacid Retail Pharmacy Market

Australia’s antacid retail pharmacy market plays an important role in providing consumers with accessible over-the-counter solutions for heartburn, indigestion, and acid-related discomfort. Community pharmacies remain a key distribution channel because consumers can conveniently purchase antacid products while receiving guidance from pharmacists regarding product selection and appropriate usage. Demand is supported by increasing digestive complaints associated with dietary habits, stress, obesity, and irregular meal patterns. Pharmacies stock diverse product formats, including chewable tablets, liquid suspensions, and combination formulations, allowing consumers to select products based on convenience and symptom severity. The expansion of pharmacy chains, independent pharmacies, and online pharmacy platforms is improving product availability nationwide. Additionally, pharmacist recommendations, promotional pricing, loyalty programs, and private-label products are influencing purchasing decisions and intensifying competition across Australia’s retail pharmacy antacid segment.

Frequently Asked Questions (FAQs) about the Australia Antacids Market Report

1. What is driving the growth of the Australia antacids market?

Australia's antacids market is growing due to the increasing prevalence of gastroesophageal reflux disease (GERD), unhealthy eating habits, obesity, alcohol consumption, and rising demand for over-the-counter digestive remedies. Expanding pharmacy networks, online retail availability, an aging population, and continuous product innovation further support sustained market growth through 2034.

2. How are product innovations supporting Australia's antacids market expansion?

Manufacturers are introducing portable and consumer-friendly antacid formulations to improve convenience and symptom relief. Recent developments include Gaviscon Chewing Gum, Bayer Australia's Rennie Spearmint Flavour tablets, and Mylanta 2GO Dual Action, offering Australians faster, more convenient options for managing heartburn, acid reflux, and indigestion.

3. What challenges are limiting growth in Australia's antacids market?

Key challenges include excessive self-medication, delayed diagnosis of serious gastrointestinal diseases, and increasing competition from proton pump inhibitors (PPIs) and H2-receptor antagonists. Growing consumer preference for long-lasting acid-suppressing therapies and lifestyle modifications is reducing reliance on traditional antacids for chronic digestive conditions.

4. Why is New South Wales the leading regional market for antacids in Australia?

New South Wales leads Australia's antacids market because of its large population, extensive healthcare infrastructure, dense pharmacy network, and strong consumer awareness of digestive health. High urbanization, busy lifestyles, increasing acid reflux cases, and expanding digital pharmacy services continue to drive strong demand for over-the-counter antacid products.

5. What factors are supporting the growth of Australia's proton pump inhibitors (PPIs) market?

Australia's PPI market is expanding due to the high prevalence of GERD, peptic ulcers, and Helicobacter pylori infections. An aging population, increasing NSAID use, availability of generic medicines, favorable reimbursement policies, and growing emphasis on evidence-based gastrointestinal treatment continue to support sustained demand for proton pump inhibitors.

6. How do retail pharmacies contribute to Australia's antacid market?

Retail pharmacies play a vital role by providing convenient access to tablet, liquid, powder, and chewable antacid products while offering pharmacist guidance for self-medication. Expanding pharmacy chains, digital healthcare services, and increasing consumer preference for preventive digestive care continue to strengthen Australia's antacid retail pharmacy market.

Market Segmentations

Drug Class

• Proton Pump Inhibitors
• H2 Antagonist
• Acid Neutralizers
• Pro-Motility Agents

Formulation Type

• Tablets
• Liquid
• Powder
• Others

Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

States

• New South Wales
• Victoria
• Queensland
• Western Australia
• South Australia
• Australian Capital Territory
• Tasmania
• Northern Territory

All the Key Players Have Been Covered

• Overview
• Key Persons
• Recent Development
• SWOT Analysis
• Revenue Analysis

Company Analysis

• Abbott Laboratories
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim International GmbH
• Dr. Reddy’s Laboratories Ltd.
• GlaxoSmithKline plc
• Johnson & Johnson
• Pfizer Inc.
• Procter & Gamble Company
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited

Report Details: